Please use this identifier to cite or link to this item: http://10.7.2.42:8080/jspui/handle/2011/9110
Title: Dor neuropática crônica hansenica: serie de casos clínicos com ênfase no diagnóstico e terapêutica com toxina botulínica tipo A
Authors: XAVIER, Marília Brasil
http://lattes.cnpq.br/0548879430701901
Keywords: Neurologia
Doença infectocontagiosa
Hanseníase
Toxina botulínica
Dor neuropática hansênica
Issue Date: 2014
Publisher: Universidade Federal do Pará
Citation: SOUSA, Emanuel de Jesus Soares de. Dor neuropática cronica hansenica: serie de casos clínicos com ênfase no diagnóstico e terapêutica com toxina botulínica tipo A. 2014. 130 f. Tese (Doutorado) – Universidade Federal do Pará, Núcleo de Medicina Tropical, Belém, 2014. Programa de Pós-Graduação em Doenças Tropicais.
Abstract: Neuropathic pain is a chronic pain syndrome is difficult to treat often affects patients with leprosy. Treatment advocates the use of analgesic, anti-inflammatory hormone or not, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without uniforms, and fully satisfactory results. OBJECTIVE: To describe patients with chronic neuropathic pain leprosy, clinical forms, damaged nerves, motor and sensory syndromes, clinical diagnosis, Electrodiagnostic, and evaluation of the WHOQOL - Bref, with emphasis on the treatment of chronic neuropathic pain using botulinum toxin type A (TxBA). METHODOLOGY: 15 patients with chronic neuropathic pain. We used specific protocol including clinical, demographic, DN4 protocol, analog scale (VAS), sensory evaluation, and motor electromyography and evaluation of the WHOQOL- Bref. Performed therapeutic intervention with botulinum toxin type A 100U BOTOX® administered subcutaneously. Patients were evaluated on days 0, 10 and 60, the WHOQOL - Bref was performed on days 0 and 60. RESULTS: The scores ranged from DN4 - 5 and 9, Analogue Scale VAS pain between 5 and 10, all patients experienced sensory changes, motor and electromyography in 01 cases there was complete pain relief in 60 days, others showed improvement in the first week with the return of symptoms with less intensity after this period, the WHOQOL - Bref comparing the moments before and after treatment with TxBA, all areas had an increase in QOL scale, areas with significant quality of life and physical. CONCLUSION: The patients had continuous, persistent refractory to standard treatment neuropathic pain of high intensity. Using TxBA proved to be a good therapeutic option in relieving the painful condition, with improved quality of life for these patients.
URI: http://repositorio.ufpa.br/jspui/handle/2011/9110
Appears in Collections:Teses em Doenças Tropicais (Doutorado) - PPGDT/NMT

Files in This Item:
File Description SizeFormat 
Tese_DorNeuropaticaCronica.pdf1,95 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons